AstraZeneca PLC's commitment to the vaccines space has been tested again after a nasal version of its COVID-19 jab came up short in a small, early-stage trial.
AstraZeneca’s Enthusiasm For Vaccines On The Wane
As COVID-19 Nasal Vaccination Trial Falters
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.
